Skip to Main content Skip to Navigation
Journal articles

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience

Abstract : Tofacitinib is an oral small molecule directed against the JAK/STAT pathway, blocking the inflammatory cascade. Oral formulation of tofacitinib has recently been approved for the treatment of patients with moderate-severe ulcerative colitis. Its efficacy and safety have been demonstrated in three phase III clinical trials and confirmed by promising real-life data. The purpose of this review is to summarize the available evidence on the efficacy and safety of tofacitinib and to define its role and position in the treatment algorithms for patients with ulcerative colitis.
Complete list of metadata

https://hal.univ-lorraine.fr/hal-02549536
Contributor : Philippe de Carvalho <>
Submitted on : Tuesday, April 21, 2020 - 3:32:42 PM
Last modification on : Tuesday, April 21, 2020 - 3:33:11 PM

Links full text

Identifiers

Citation

Ferdinando D’amico, Tommaso Lorenzo Parigi, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therapeutic Advances in Gastroenterology, Sage Publishing, 2019, 12, pp.175628481984863. ⟨10.1177/1756284819848631⟩. ⟨hal-02549536⟩

Share

Metrics

Record views

22